Literature DB >> 8118802

Evidence for selection against human lung cancers bearing p53 missense mutations which occur within the HLA A*0201 peptide consensus motif.

E A Wiedenfeld1, M Fernandez-Viña, J A Berzofsky, D P Carbone.   

Abstract

Short peptide fragments of intracellular proteins that fit a defined sequence motif bind to the most common human major histocompatibility complex class I molecule, HLA A*0201, and mediate killing by cytotoxic T-cells [D.F. Hunt et al., Science (Washington DC), 255: 1261-1263, 1992; K. Falk et al., Nature (Lond.), 351: 290-296, 1991]. The existence of such a motif allows prediction of whether novel peptides derived from mutant oncoporteins might be presented on the surface of cancer cells bearing that HLA allele. Clinical cancer might develop only when these mutations occur outside a major histocompatibility complex binding motif or in those cells that acquire defects in antigen presentation. Here, we find that missense mutations of p53 from a variety of tumors fall within the HLA A*0201 motif less often than would be expected if the location of mutations and motifs were independent. When we analyzed the HLA subtype of lung cancer cell lines with known p53 missense mutations, we found that all of the mutant oncopeptides predicted to be presentable by HLA A*0201 came from tumors that either did not carry the A*0201 allele or had lost that allele in the process of tumorigenesis. Presentation of mutant oncogene peptides on class I major histocompatibility complex might thus represent a physiologically significant selection pressure in the development of human cancer.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8118802

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  16 in total

Review 1.  T-cell recognition of self peptides as tumor rejection antigens.

Authors:  Y Kawakami; S A Rosenberg
Journal:  Immunol Res       Date:  1996       Impact factor: 2.829

2.  p53-Reactive T Cells Are Associated with Clinical Benefit in Patients with Platinum-Resistant Epithelial Ovarian Cancer After Treatment with a p53 Vaccine and Gemcitabine Chemotherapy.

Authors:  Nicola R Hardwick; Paul Frankel; Christopher Ruel; Julie Kilpatrick; Weimin Tsai; Ferdynand Kos; Teodora Kaltcheva; Lucille Leong; Robert Morgan; Vincent Chung; Raechelle Tinsley; Melissa Eng; Sharon Wilczynski; Joshua D I Ellenhorn; Don J Diamond; Mihaela Cristea
Journal:  Clin Cancer Res       Date:  2018-01-04       Impact factor: 12.531

3.  Next-generation sequencing reveals new information about HLA allele and haplotype diversity in a large European American population.

Authors:  Lisa E Creary; Sridevi Gangavarapu; Kalyan C Mallempati; Gonzalo Montero-Martín; Stacy J Caillier; Adam Santaniello; Jill A Hollenbach; Jorge R Oksenberg; Marcelo A Fernández-Viña
Journal:  Hum Immunol       Date:  2019-07-22       Impact factor: 2.850

Review 4.  Non-Small-Cell Lung Cancer: Role of the Immune System and Potential for Immunotherapy.

Authors:  David P Carbone; David R Gandara; Scott J Antonia; Christoph Zielinski; Luis Paz-Ares
Journal:  J Thorac Oncol       Date:  2015-07       Impact factor: 15.609

Review 5.  Intratumoral immunotherapy: using the tumour against itself.

Authors:  Marka R Crittenden; Uma Thanarajasingam; Richard G Vile; Michael J Gough
Journal:  Immunology       Date:  2005-01       Impact factor: 7.397

6.  Heterologous prime/boost immunization with p53-based vaccines combined with toll-like receptor stimulation enhances tumor regression.

Authors:  Hidenobu Ishizaki; Guang-Yun Song; Tumul Srivastava; Kyla Driscoll Carroll; Vafa Shahabi; Edwin R Manuel; Don J Diamond; Joshua D I Ellenhorn
Journal:  J Immunother       Date:  2010 Jul-Aug       Impact factor: 4.456

Review 7.  Immunobiology and immunotherapy of head and neck cancer.

Authors:  T L Whiteside
Journal:  Curr Oncol Rep       Date:  2001-01       Impact factor: 5.075

8.  Tumor escape from immune recognition: lethal recurrent melanoma in a patient associated with downregulation of the peptide transporter protein TAP-1 and loss of expression of the immunodominant MART-1/Melan-A antigen.

Authors:  M J Maeurer; S M Gollin; D Martin; W Swaney; J Bryant; C Castelli; P Robbins; G Parmiani; W J Storkus; M T Lotze
Journal:  J Clin Invest       Date:  1996-10-01       Impact factor: 14.808

9.  Tumour-infiltrating lymphocytes mediate lysis of autologous squamous cell carcinomas of the head and neck.

Authors:  J Hald; N Rasmussen; M H Claesson
Journal:  Cancer Immunol Immunother       Date:  1995-10       Impact factor: 6.968

10.  The cancer exome generated by alternative mRNA splicing dilutes predicted HLA class I epitope density.

Authors:  Thomas Stranzl; Mette V Larsen; Ole Lund; Morten Nielsen; Søren Brunak
Journal:  PLoS One       Date:  2012-09-25       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.